Lumateperone is a novel antipsychotic agent with a unique mechanism of
action with high 5-hydroxytryptamine 2A(5-HT2A) blocking activity. A
Phase 2 study in treatment of insomnia revealed strong evidence of
efficacy, with no impairment of next-day cognition.
